You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Blockade of histamine-releasing factor as a new prophylactic and therapeutic strategy for food allergy
SBC: ABWIZ BIO INC Topic: NIAIDDESCRIPTION provided by applicant The prevalence of food allergy has been dramatically increasing for the last few decades Food Allergy and Anaphylaxis Network www foodallergy org estimates that up to million Americans have food allergies Six to eight percent of children under the age of three have food allergies and nearly four percent of adults have them Signs and symptoms of food all ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAIDDESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors
SBC: NEONC TECHNOLOGIES INC Topic: BTDESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Reagents to Create Large DNA Constructs in One Assembly Step
SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC Topic: 100DESCRIPTION provided by applicant To many notably Craig Venter andquot synthetic biologyandquot means simply andquot synthesizing large amounts of DNAandquot This type of synthetic biology actually began in the andapos s when Caruthers introduced a phosphoramidite based solid phase DNA synthesis architecture This allowed ICI and the Benner group to synthesize complete genes encoding ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes
SBC: REMD BIOTHERAPEUTICS INC. Topic: NIDDKDESCRIPTION provided by applicant Fast Track Insulin remains the primary and often the only treatment for type diabetes mellitus T D However it is associated with chronic iatrogenic hyperinsulinemia secondary hyperlipidemia higher incidence and severity of cardiovascular complications and life threatening hypoglycemia events A higher mortality vs due to cardiovascular ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
"Extra Innings”: Using Serious Gaming and the Science of Baseball to Teach Science and Mathematics
SBC: DFUSION INC. Topic: 999DESCRIPTION provided by applicant Due to the rapid advances in science technology engineering and mathematics STEM the United States has been at the forefront of innovation and technology development in the science health and biomedical fields However these continuing advances are in jeopardy as there is a growing national shortage of trained STEM workers While the need for a STEM li ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
High Fidelity Computational Models for Aggregated Tissue Interaction in Surgical Simulations
SBC: CFD RESEARCH CORPORATION Topic: DHP16A001Surgical simulations aiming to support surgeon practices and medical education have attracted enormous research effort over the last two decades. However, the physical reality, especially on simulating aggregated tissue interaction, is still unsatisfactory. In this proposed work, an open source surgery simulation framework, SoFMIS, will be utilized and enhanced with tissue interaction models to a ...
STTR Phase I 2016 Department of DefenseDefense Health Agency -
Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis
SBC: Stemsynergy Therapeutic Topic: 102DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis FAP an orphan disease while somatic mutations lead to spo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
improving Cas9 mediated homologous recombination in pluripotent stem cells
SBC: APPLIED STEMCELL, INC. Topic: 200DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health